RR

Ranga Rao Yama

Active Director Director DIN 09162664
DIN 09162664 First appointment Apr 2021 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Apr 2021
Shareholding value •••• Premium profile

About Ranga Rao Yama

Data last updated:

Ranga Rao Yama is a Director at Megaclite Pharmaceuticals Private Limited (since 2021). The company operates in Pharma. Megaclite Pharmaceuticals Private Limited reported revenue of ₹1.43 Cr (FY 2023).

DIN 09162664
Primary Designation Director
Industry Pharma
First Appointment 30 Apr 2021
Oldest Company Age 5 yrs
Largest company Megaclite Pharmaceuticals Private Limited · ₹1.43 Cr (FY 2023)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director30 Apr 20212021₹1.43 Cr (FY 2023)Active

Board colleagues of Ranga Rao Yama

Directorship timeline

Open interactive timeline →
Megaclite Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Ranga Rao Yama

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ranga Rao Yama

Ranga Rao Yama currently holds 1 directorship: Megaclite Pharmaceuticals Private Limited (Director, since 30 Apr 2021, revenue ₹1.43 Cr (FY 2023)).

Ranga Rao Yama was first appointed on 30 Apr 2021 as Director at Megaclite Pharmaceuticals Private Limited.

The current boards of Ranga Rao Yama's companies include Begum Sumayya (Megaclite Pharmaceuticals Private Limited), Shaik Chandini (Megaclite Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available